BeloGal® platform is applicable for lung-targeted delivery of Meropenem
The first step of the biodistribution study of Belopenem in rats has been successfully completed. Double Bond Pharmaceutical combined the BeloGal®platform with the well-known antibiotic Meropenem, giving rise to two working Belopenem formulations. The recent study showed a superior lung-targeted delivery of Meropenem through the formulations, when compared to the standard intravenous Meropenem solution. The study is expected to be completed in December 2019 – January 2020. “I am very glad that we are able to validate the BeloGal®platform for lung-targeting of an additional API –